Latest News and Press Releases

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for...

ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England &...

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA,...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7...

Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023;...

Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a...

Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3...